New Jerseyan Insmed 'up for the rising' after US FDA lifts CF hold
This article was originally published in Scrip
As if it had the power of fellow New Jerseyan Bruce Springsteen driving it on 7 May, biopharma Insmed was "up for the rising," with its shares soaring nearly 83% after the US FDA lifted the clinical hold it imposed last summer on the company’s programme for Arikace (liposomal amikacin for inhalation) in cystic fibrosis (CF) patients with Pseudomonas lung infections.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.